Long Beach, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Glauconix Biosciences, Inc. will be presenting biomarker data in human donor tissue related to the mechanism of action of Emerald’s lead drug candidate, NB1111, a prodrug of tetrahydrocannabinol (THC-valine-hemisuccinate; THCVHS), at the 2019 American Academy of Ophthalmology Annual Meeting (AAO) being held October 12 -15, 2019, at the Moscone Center in San Francisco, CA.
Details of the poster presentation are as follows:
Title: IOP-Lowering Ability of NB-1111 Active Moiety, THC, in a Human Tissue Model
Session: SYM22 The Innovators Symposium
Date and time: Sunday, October 13, 2019, 12:15 – 1:15 PM PT
Location: Moscone Center, ePoster Lounge, Station 3
Additionally, the company will be featured in a poster session showcasing NB1111 superiority in lowering intraocular pressure (IOP) in a validated animal model, compared to the current standard-of-care, latanoprost, a prostaglandin-based therapy, for the treatment of glaucoma. The experiments were performed by researchers at the University of Mississippi and will be presented via an e-poster format at AAO.
Details of the e-poster session are as follows:
Title: IOP Profiles Following Single-Dose Δ9-Tetrahydrocannabinol-Valine-Hemisuccinate (NB1111) Nanoemulsion and Latanoprost
Date and time: Saturday, Oct 12, 2019, 9:00 AM - Tuesday, Oct 15, 2019, 1:00 PM
Location: Moscone Center
About Glauconix Biosciences
Glauconix Biosciences is a leading developer of ophthalmic ex-vivo dynamic 3D human tissue models for accelerating therapeutic innovation and drug discovery. Their 3D tissue models can de-risk ophthalmic assets and expedite drug development. Glauconix adds value to their clients and partners by expediting early identification and validation of effective compounds or biologics in the preclinical phase and those entering clinical trials. To learn more about Glauconix Biosciences, visit www.glauconix-biosciences.com
About the University of Mississippi
The University of Mississippi, the state's flagship institution, is among the elite group of R-1: Doctoral Universities - Highest Research Activity in the Carnegie Classification. The university has a long history of producing leaders in public service, academics, research and business. Its 15 academic divisions include a major medical school, nationally recognized schools of accountancy, law and pharmacy, and an Honors College acclaimed for a blend of academic rigor, experiential learning and opportunities for community action.
About Emerald Bioscience, Inc.
Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Emerald's strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.
Emerald Bioscience is part of the Emerald Group, which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.
For more information, visit www.emeraldbio.life
CONTACT
Emerald Bioscience Investor Relations
Emerald Health Sciences
Karam Takhar
Email: ir@emeraldbio.life
Phone: 949-336-3437
Douglas Cesario
Chief Financial Officer
Email: doug@emeraldbio.life
Phone: 949-336-3437
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development, business strategy, product branding, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Emerald may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Emerald’ most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Emerald disclaims any intent or obligation to update these forward-looking statements.